Shire, Actavis Facing Federal Antitrust Class Action Lawsuit
Last Updated on May 8, 2018
Picone v. Shire U.S. Inc. et al
Filed: January 11, 2017 ◆§ 1:16-cv-12396
A New York state stock corporation is behind a proposed antitrust class action claiming four defendants engaged in an anti-competition conspiracy.
A New York state stock corporation is behind a proposed antitrust class action claiming four defendants—Shire LLC, Shire U.S., Inc., Actavis Elizabeth LLC and Actavis LLC—engaged in an anti-competition conspiracy to fix the market for the attention-deficit/hyperactivity disorder drug Intuniv. The 38-page complaint, filed in Massachusetts district court, alleges that in 2013 Shire entered into an unlawful non-competition agreement with Actavis in which the latter “agreed to delay marketing its less-expensive generic version” of Intuniv for nearly two years. In exchange, the lawsuit continues, Shire agreed to repay its co-defendant “effectuating a payment of tens of millions of dollars” in the form of not launching an authorized generic that would directly compete with Actavis’s generic during its 180-day exclusivity period.
Hair Relaxer Lawsuits
Women who developed ovarian or uterine cancer after using hair relaxers such as Dark & Lovely and Motions may now have an opportunity to take legal action.
Read more here: Hair Relaxer Cancer Lawsuits
Stay Current
Sign Up For
Our Newsletter
New cases and investigations, settlement deadlines, and news straight to your inbox.
Before commenting, please review our comment policy.